

# **BEHAVIORAL HEALTH**HEDIS® CODING GUIDE

2022 - 2023 Georgia Medicaid



This guide provides HEDIS coding information only, not necessarily payment guidance. Refer to your state's guidance for payment details and telehealth regulations.

#### **MEASURE**

### Follow-Up After Hospitalization for Mental Illness (FUH)

6 years and over

# DESCRIPTION OF MEASURE

The percentage of discharges for members six years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses AND who had a follow-up visit with a mental health provider.

### Two rates are reported:

- The percentage of discharges for which the member received follow-up within 30 days after discharge.
- 2. The percentage of discharges for which the member received follow-up within seven days after discharge.

#### **GOALS**

This measure addresses the need for coordination of care immediately after hospitalization, which is a higher risk time for readmissions and suicide completions.

Follow-up within seven days after date of inpatient discharge with a qualified mental health provider\*. Do not include visits that occur on the date of discharge.

#### **Mental Health providers include:**

Psychiatrist, Psychologist, Psychiatric Nurse Practitioner (NP) or Clinical Nurse Specialist (CNS), Masters-Prepared Social Worker (MSW), Certified or Licensed Marital and Family Therapist (MFT) or Licensed Professional Counselor (PC, PCC, PCC-S), Physician Assistant certified to practice psychiatry, an authorized Certified Community Mental Health Center (CMHC or the comparable term used within the state in which it is located), or an authorized Certified Community Behavioral Health Clinic (CCBHC). Note: Only authorized CMHCs and CCBHCs are considered mental health providers.

\*Follow up with a PCP does NOT fulfill the follow up requirement for this measure unless they meet criteria listed above.

# COMPLIANCE CODES & MEASURE TIPS

**Outpatient Visit, Visit Setting Unspecified CPT®:** 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55

- WITH -

**P0S:** 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72

- OR -

Telehealth Visit, Visit Setting Unspecified CPT

- WITH -

**POS:** 02, 10

- OR -

**Behavioral Health (BH) Outpatient Visit CPT:** 98960-62, 99078, 99201-05, 99211-15, 99241-45, 99341-45, 99347-50, 99381-87, 99391-97, 99401-04, 99411-12, 99483, 99492-94, 99510

- OR -

**HCPCS:** G0155, G0176-77, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036-37, H0039-40, H2000, H2010-11, H2013-20, T1015

- OR -

**UBREV:** 0510, 0513, 0515-17, 0519-23, 0526-29, 0900, 0902-04, 0911, 0914-17, 0919, 0982-83

- OR -

**Intensive Outpatient / Partial Hospitalization** 

Option 1:

**HCPCS:** G0410-11, H0035, H2001, H2012, S0201, S9480, S9484-85

**UBREV:** 0905, 0907, 0912-13

Option 2:

Visit Setting Unspecified CPT

- WITH -

**POS:** 52



MEASURE	DESCRIPTION OF MEASURE	GOALS	COMPLIANCE CODES & MEASURE TIPS
Follow-Up After Hospitalization for Mental Illness (FUH) 6 years and over		Telehealth visits with appropriate codes and any listed mental health provider-type is sufficient to qualify for this measure.	- OR -  CMHC Visit POS: 53 - WITH -  Visit Setting Unspecified CPT - OR -  BH Outpatient Codes - OR -  Observation Visit  CPT: 99217-20 - OR -  TCM Services  CPT: 99495-96 - OR -  BH Setting Visit  UBREV: 0513, 0900-05, 0907, 0911-17, 0919 - OR -  Observation Visit  CPT: 99217-20 - OR -  Telephone Visit  CPT: 98966-68, 99441-43 - OR -  Psychiatric Collaborative Care  Management  CPT: 99492-94  HCPCS: G0512 - OR -  Electroconvulsive Therapy  CPT: 90870  ICD-10-PCS: GZB0ZZZ, GZB1ZZZ, GZB2ZZZ, GZB3ZZZ, GZB4ZZZ - WITH -  POS: 03, 05, 07, 09, 11-20, 22, 24, 33, 49, 50, 52, 53, 71, 72
Follow-Up After Emergency Department Visit for Mental Illness (FUM) 6 years and over	The percentage of emergency department (ED) visits for members six years of age and older with a principal diagnosis of mental illness or intentional self-harm and who had a follow-up visit for a mental illness.	This measure addresses need for coordination of care immediately after an ED visit, which is a higher risk time for readmissions and suicide completions.  Follow-up within seven days after date of ED visit with any practitioner. The follow-up visit must list a primary mental illness diagnosis or intentional self-harm.	Outpatient Visit, Visit Setting Unspecified CPT: 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55  — WITH —  POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72  Telehealth Visit, Visit Setting Unspecified CPT  — WITH —  POS: 02, 10  — OR —  BH Outpatient Visit CPT: 98960-62, 99078, 99201-05, 99211-15, 99241-45, 99341-45, 99347-50, 99381-87, 99391-97, 99401-04, 99411-12, 99483, 99492-94, 99510  HCPCS: G0155, G0176-77, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036-37, H0039-40, H2000, H2010-11, H2013-20, T1015  UBREV: 0510, 0513, 0515-17, 0519-23, 0526-29, 0900, 0902-04, 0911, 0914-17, 0919, 0983

MEASURE	DESCRIPTION OF MEASURE	DOCUMENTATION TIPS	COMPLIANCE CODES & MEASURE TIPS
Follow-Up After Emergency Department Visit for Mental Illness (FUM) 6 years and over	Two rates are reported:  1. The percentage of ED visits for which the member received follow-up within 30 days of the ED visit.  2. The percentage of ED visits for which the member received follow-up within seven days of the ED visit.	Telehealth visits with appropriate codes and primary mental illness diagnoses or intentional self-harm are sufficient to qualify for this measure.	Intensive Outpatient/Partial Hospitalization   Option 1:
Follow-Up After Emergency Department Visit for Substance Use (FUA) 13 years and over	The percentage of emergency department (ED) visits for members 13 years of age and older with a <i>principal</i> diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose.	This measure addresses the need for a member to have access to outpatient services for coordination of care in the community-based treatment setting and not use the ED for ongoing SUD services when not medically necessary.  Follow-up within seven days after date of ED visit with any practitioner. The follow-up visit must list a principal diagnosis of SUD (alcohol or other drug [AOD] abuse or dependence) or any diagnosis of drug overdose.	Outpatient Visit, Visit Setting Unspecified CPT: 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55  — WITH — POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72  — OR — BH Outpatient Visit CPT: 98960-62, 99078, 99201-05, 99211-15, 99241-45, 99341-45, 99347-50, 99381-87, 99391-97, 99401-04, 99411-12, 99483, 99492-94, 99510 HCPCS: G0155, G0176-77, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036-37, H0039-40, H2000, H2010-11, H2013-20, T1015 UBREV: 0510, 0513, 0515-17, 0519-23,

**UBREV:** 0510, 0513, 0515-17, 0519-23, 0526-29, 0900, 0902-04, 0911, 0914-17,

0919, 0982-83

### MEASURE

### Follow-Up After Emergency Department Visit for Substance Use (FUA)

13 years and over

### DESCRIPTION OF MEASURE

#### Two rates are reported:

- The percentage of ED visits for which the member received follow-up within 30 days of the ED visit.
- 2. The percentage of ED visits for which the member received follow-up within seven days of the ED visit.

Pharmacotherapy dispensing events count towards follow-up:

- Alcohol use disorder (AUD) treatment medications
- Opioid use disorder (OUD) treatment medications
- Alcohol or other drug (AOD) medication treatment
- OUD weekly drug treatment service
- Substance use service

#### **GOALS**

Telehealth visits with any diagnosis of SUD or drug overdose are sufficient to qualify for this measure.

AUD treatment medications:

- Disulfiram (oral)
- Naltrexone (oral and injectable)
- Acamprosate (oral, delayed-release tablet)

OUD treatment medications:

- Naltrexone (oral and injectable)
- Buprenorphine (sublingual tablet)
- Buprenorphine (injection)
- Buprenorphine (implant)
- Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film)

## COMPLIANCE CODES & MEASURE TIPS

- OR -

# Intensive Outpatient Encounter or Partial Hospitalization

Option 1: Visit Setting Unspecified CPT

- WITH -

**POS:** 52

Option 2: Intensive Outpatient or Partial Hospitalization

**HCPCS:** G0410-11, H0035, H2001, H2012, S0201, S9480, S9484-85

**UBREV:** 0905, 0907, 0912-13

- OR -

Non-residential Substance Abuse Treatment Facility Visit, Visit Setting Unspecified CPT

- WITH -

**POS:** 57, 58

- OR -

**CMHC Visit, Visit Setting Unspecified** 

- WITH -

**POS:** 53

- OR -

**Observation Visit CPT:** 99217-20

Telehealth Visit, Visit Outpatient Setting Unspecified CPT

- WITH -

Telehealth POS: 02, 10

- OR -

**Telephone Visits** 

**CPT:** 98966-68, 99441-43

- OR -

**Online Assessments** 

**CPT:** 98969-72, 99421-23, 99444, 99457-58 **HCPCS:** G0071, G2010, G2012, G2061-63, G2250-52

- OR -

Peer Support Services (requires a diagnosis in one of the lists above)

**HCPCS:** G0177, H0024-25, H0038-40, H0046, H2014, H2023, S9445, T1012, T1016

- OR -

**OUD Monthly Based Treatment** 

**HCPCS:** G2086-87

– OR –

**OUD Weekly Non Drug** 

**HCPCS:** G2071, G2074-77, G2080

**SUD Services** 

**CPT:** 99408-09

**HCPCS:** G0396-97, G0443, H0001, H0005, H0007, H0015-16, H0022, H0047, H0050,

H2035-36, T1006, T1012 **UBREV:** 0906, 0944-45

MEASURE	DESCRIPTION OF MEASURE	GOALS	COMPLIANCE CODES & MEASURE TIPS
Follow-Up After Emergency Department Visit for Substance Use (FUA) 13 years and over			- OR - Substance Use Services HCPCS: H0006, H0028 - OR -  BH Assessment CPT: 99408-09 HCPCS: G0396-97, G0442, G2011, H0001-02, H0031, H0049  Pharmacotherapy Dispensing Event AOD Medication Treatment HCPCS: G2069-70, G2072-73, H0020, H0033, J0570-75, J2315, Q9991-92, S0109 - OR -  OUD Weekly Drug Treatment HCPCS: G2067-70, G2072-73
Initiation and Engagement of Substance Use Disorder Treatment (IET) 13 years and over	The percentage of new SUD episodes that result in treatment initiation and engagement.  Two rates are reported:  1. Initiation of SUD Treatment: The percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth visit or medication assisted treatment (MAT) within 14 days.  2. Engagement of SUD Treatment: The percentage of new SUD episodes that have evidence of treatment engagement within 34 days of initiation.	Adolescents and adults with new episodes of SUD abuse or dependence are receiving initiation and engagement into SUD treatment.  For all initiation events except medication treatment, initiation on the same day as the earliest diagnosis of SUD abuse or dependence must be with different providers in order to count.  Timely access to SUD services increases the chance that the member will engage in services when they demonstrate readiness.  SUD episodes in the opioid use disorder cohort (criteria does not require a diagnosis in the lists to the right).  Naltrexone Injection HCPCS: G2073, J2315  Buprenorphine Oral HCPCS: H0033, J0571  Buprenorphine Oral, Weekly HCPCS: G2068, G2079  Buprenorphine Injection HCPCS: G2069, Q9991-92  Buprenorphine Implant HCPCS: G2070, G2072, J0570  Buprenorphine Naloxone HCPCS: J0572-75	Alcohol Abuse and Dependence ICD-10: F10.1029  Opioid Abuse and Dependence ICD-10: F11.1029  Other Drug Abuse and Dependence ICD-10: F12.10-F19.29  With any of the following  Acute/Nonacute Inpatient Stay UBREV: 0100-01, 0110-04, 0116-24, 0126-34, 0136-44, 0146-54, 0156-60, 0164, 0167, 0169-74, 0179, 0190-94, 0199-0204, 0206-14, 0219, 1000-02  — OR —  Outpatient Visit, Visit Setting Unspecified CPT: 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-23, 99238-39, 99251-55  — WITH —  POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72  — OR —  BH Outpatient Visit CPT: 98960-62, 99078, 99201-05, 99211-15, 99241-45, 99341-45, 99347-50, 99381-87, 99391-97, 99401-04, 99411-12, 99483, 99492-94, 99510  — OR —  HCPCS: G0155, G0176-77, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036-37, H0039-40, H2000, H2010-11, H2013-20, T1015

MEASURE	DESCRIPTION	GOALS	COMPLIANCE CODES &
Initiation and Engagement of Substance Use Disorder Treatment (IET) 13 years and over	OF MEASURE	Methadone Oral HCPCS: H0020, S0109  Methadone Oral, Weekly HCPCS: G2067, G2078	## Code: 0510, 0513, 0515-17, 0519-23, 0526-29, 0900, 0902-04, 0911, 0914-17, 0919, 0982-83  ## Code: 0510, 0513, 0515-17, 0519-23, 0526-29, 0900, 0902-04, 0911, 0914-17, 0919, 0982-83  ## Code: 0R ─ Intensive Outpatient/Partial Hospitalization Option 1:  ## CPCS: G0410-11, H0035, H2001, H2012, S0201, S9480, S9484-85  ## Revenue Code: 0905, 0907, 0912-13  ## Option 2:  ## Visit Setting Unspecified CPT  ## WITH ─ POS: 52  ## OR ─ Non-residential Substance Abuse  ## Treatment Facility Visit, Visit Setting  ## Unspecified CPT  ## WITH ─ POS: 57, 58  ## OR ─ CMHC Visit, Visit Setting Unspecified CPT  ## WITH ─ CMHC POS: 53  ## OR ─ CM ─ C

MEASURE	DESCRIPTION OF MEASURE	GOALS	COMPLIANCE CODES & MEASURE TIPS
Initiation and Engagement of Substance Use Disorder Treatment (IET) 13 years and over			- OR - OUD Weekly Drug Treatment HCPCS: G2067-70, G2072-73 - OR - OUD Weekly Non-Drug HCPCS: G2071, G2074-77, G2080 SUD episodes in the AUD cohort (criteria does not require a diagnosis in the lists above) Naltrexone Injection HCPCS: G2073, J2315
Antidepressant Medication Management (AMM) 18 years and over	The percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment.  Two rates are reported:  1. Effective Acute Phase Treatment: The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks).  2. Effective Continuation Phase Treatment: The percentage of members who remained on an antidepressant medication for at least 180 days (6 months).		Compliance occurs only if patient fills prescription. Encourage patient to fill prescriptions on time and take medications as prescribed.  Major Depression: F32.0-F32.4, F32.9, F33.0-F33.3, F33.41, F33.9
Follow-Up Care for Children Prescribed ADHD Medication (ADD) 6-12 years	The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed.	Do not count a visit on the earliest prescription dispensing date for ADHD medication as the Initiation Phase visit.  One of the C&M visits must be face-to-face with the patient.  Members need to be monitored to ensure that prescription was filled during first 30 days and adjusted to optimal therapeutic effect. Monitoring during an episode is important for adherence, response to treatment, and monitoring for adverse effects so that adjustments can be made as needed.	Evidence of three visits within 10 months, one of the three within the first 30 days.  Initiation Phase: Any of the following Outpatient with POS CPT: 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55 With POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72  — OR — BH Outpatient CPT: 98960-62, 99078, 99201-05, 99211-15, 99241-45, 99341-45, 99347-50, 99381-87, 99391-97, 99401-04, 99411-12, 99483, 99492-94, 99510 HCPCS: G0155, G0176-77, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036-37, H0039-40, H2000, H2010-11, H2013-20, T1015

H2013-20, T1015

MEASURE	DESCRIPTION OF MEASURE	GOALS	COMPLIANCE CODES & MEASURE TIPS
Follow-Up Care for Children Prescribed ADHD Medication (ADD) 6-12 years	Two rates are reported.  1. Initiation Phase: The percentage of members 6-12 years of age with a prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase.  2. Continuation and Maintenance (C&M) Phase: The percentage of members 6-12 years of age who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.		Revenue Code: 0510, 0513, 0515-17, 0519-23, 0526-29, 0900, 0902-04, 0911, 0914-17, 0919, 0982-83  - OR -  Observation CPT: 99217-20  - OR -  Health and Behavior Assessment or Intervention  CPT: 96150-54, 96156, 96158-59, 96164-65, 96167-68, 96170-71  - OR -  Intensive Outpatient or Partial  Hospitalization  CPT: 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55  With Partial Hospitalization  POS: 52  - OR -  Partial Hospitalization/Intensive Outpatient  HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484-85  Revenue Code: 0905, 0907, 0912-13  - OR -  Community Mental Health and POS  CPT: 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55  With POS: 53  - OR -  Telehealth and POS  CPT: 90791-94, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55  With POS: 02  - OR -  Telephone Visit  CPT: 98966-68, 99441-43  Continuation and Maintenance (C&M)  Phase  Any of the above codes, or one visit can be e-visit or virtual check-in  CPT: 98969-72, 99421-24, 99457  HCPCS: G0071, G2010, G2012, G2061-63

MEASURE	DESCRIPTION OF MEASURE	DOCUMENTATION TIPS	COMPLIANCE CODES & MEASURE TIPS
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) 1-17 years	The percentage of children and adolescents 1-17 years of age who had two or more antipsychotic prescriptions and had metabolic testing.  Three rates are reported. The percentage of children and adolescents on antipsychotics who:  1. Received blood glucose testing  2. Received cholesterol testing  3. Received blood glucose and cholesterol testing	Certain antipsychotic medications can increase risk for development of diabetes and hyperlipidemia. Metabolic monitoring increases recognition and allows for early intervention.	Glucose/HbA1c CPT: 80047-48, 80050, 80053, 80069, 82947, 82950-51, 83036 CPT II: 3044F, 3046F, 3051F, 3052F  LDL/Other Cholesterol CPT: 80061, 82465, 83700-01, 83704, 83718, 83721, 84478 CPT II: 3048F, 3049F, 3050F  Note: CPT II codes are for quality reporting purposes only, not for payment
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) 18 years and over	The percentage of members 18 years and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed, and remained on, an antipsychotic medication for at least 80% of their treatment period.	This measure addresses the need for adults who begin an antipsychotic medication to treat schizophrenia to remain on medication for at least 80% of their treatment period.  The treatment period is the period of time beginning on the earliest antipsychotic medication prescription date through the last day of the measurement year.  Adherence to medication increases likelihood of recovery.	Compliance occurs only if patient has prescriptions filled 80% of days from their initial antipsychotic medication prescription.  Encourage patient to fill prescriptions on time and take medications as prescribed.
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) 18-64 years	The percentage of members 18-64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease, who had an LDL-C test during the measurement year.	Antipsychotic medication can cause dyslipidemia, which can worsen cardiovascular disease. Monitoring increases chance to intervene for best outcomes.	CPT: 80061, 83700-01, 83704, 83721 CPT II: 3048F, 3049F, 3050F  Note: CPT II codes are for quality reporting purposes only, not for payment.
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD) 18-64 years	The percentage of members 18-64 years of age with schizophrenia or schizoaffective disorder and diabetes who had both an LDL-C test and an HbA1c test during the measurement year.	Antipsychotic medication can cause metabolic problems and worsen the course of diabetes if not discovered. Monitoring increases chance to intervene for best outcomes.	HbA1c CPT: 83036-37 CPT II: 3044F, 3046F, 3051F, 3052F  LDL CPT: 80061, 83700-01, 83704, 83721 CPT II: 3048F, 3049F, 3050F  Note: CPT II codes are for quality reporting purposes only, not for payment.
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) 18-64 years	The percentage of members 18-64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement	Measure addresses the need for adults diagnosed with schizophrenia OR bipolar disorder to have EITHER a glucose test or an HbA1c test.  Antipsychotic medication can cause metabolic problems and worsen the course of diabetes if not discovered. Monitoring increases chance to interpope for best outcomes.	Glucose / HbA1c CPT: 80047-48, 80050-53, 80069, 82947, 82950-51, 83036-37 CPT II: 3044F, 3046F, 3051F, 3052F  Note: CPT II codes are for quality reporting purposes only, not for payment.

intervene for best outcomes.

year.

MEASURE	DESCRIPTION OF MEASURE	GOALS	COMPLIANCE CODES & MEASURE TIPS
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) 1-17 years	The percentage of children and adolescents 1-17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.	Documentation of psychosocial care as a first-line treatment for children and adolescents.  Exclusions:  • At least one acute inpatient encounter with diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, autism, or other developmental disorder.  • At least 2 visits in an outpatient, intensive outpatient, or partial hospitalization setting.	Psychosocial Care CPT: 90832-34, 90836-40, 90845-47, 90849, 90853, 90875-76, 90880 HCPCS: G0176-77, G0409-11, H0004, H0035-40, H2000-01, H2011-14, H2017-20, S0201, S9480, S9484-85
Use of Opioids at High Dosage (HDO) 18 years and over	The percentage of members 18 years of age and older who received prescription opioids at a high dosage (average morphine milligram equivalent dose [MME]) ≥ 90 mg) for ≥ 15 days during the measurement year.  Note: A lower rate indicates better performance	Reduce the number of adults prescribed high dose opioids for ≥ 15 days. A lower rate indicates better performance.  Increasing total MME dose of opioids is related to increased risk of overdose and adverse events. Necessity of use of high doses should be clear.	Members are considered out of compliance if their prescription average MME was ≥ 90mg MME during the treatment period.  This measure does not include the following opioid medications: • Injectables • Opioid cough and cold products • Ionsys® (fentanyl transdermal patch) • Methadone for the treatment of OUD  Exclusions: • Members with cancer, sickle cell disease • Members receiving palliative care
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 13 years and over	The percentage of acute inpatient hospitalizations, residential treatment or withdrawal management visits for a diagnosis of SUD among members 13 years of age and older that result in a follow-up visit or service for SUD.  Two rates are reported:  1. The percentage of visits or discharges for which the member received follow-up for SUD within the 30 days after the visit or discharge.  2. The percentage of visits or discharges for which the member received follow-up for SUD within seven days after the visit or discharge.	For both indicators, any of the following meet criteria for a follow-up visit:  • An inpatient admission or residential BH stay with a principal diagnosis of SUD  • Outpatient, intensive outpatient encounter, observation visit, partial hospitalization, non-residential substance abuse treatment facility, or CMHC visit with a principal diagnosis of SUD  • Telehealth visit, or SUD service with a principal diagnosis of SUD  • Opioid treatment service that bills monthly or weekly or residential BH treatment with a principal diagnosis of SUD  • Telephone, e-visit or virtual check-in with a principal diagnosis of SUD  • Telephone, te-visit or virtual check-in with a principal diagnosis of SUD  • Pharmacotherapy dispensing event or medication treatment event  Note: Follow-up does not include detoxification.	Alcohol Abuse and Dependence ICD-10-CM: F10.10, F10.120-21, F10.129-32, F10.139, F10.14, F10.150-51, F10.159, F10.180-82, F10.239, F10.24, F10.250-51, F10.259, F10.2627, F10.280-82, F10.288, F10.29  Opioid Abuse and Dependence ICD-10-CM: F11.10, F11.120-22, F11.129, F11.13-14, F11.150-51, F11.159, F11.181-82, F11.188, F11.19, F11.20, F11.220-22, F11.229, F11.2324, F11.250-51, F11.259, F11.281-82, F11.288, F11.29  SUD Medication Treatment HCPCS: G2069-70, G2072-73, H0020, H0033, J0570-75, J2315, Q9991-92, S0109  SUD Services CPT: 99408-09 HCPCS: G0396-97, G0443, H0001, H0005, H0007, H0015-16, H0022, H0047, H0050, H2035-36, T1006, T1012 UBREV: 0906, 0944-45  OUD Monthly Office-Based Treatment HCPCS: G2086-87

Documentation Tips:   Discuss importance of timely recommended follow-up visits. Use Disorder (FUI)	MEASURE	DESCRIPTION OF MEASURE	GOALS	COMPLIANCE CODES & MEASURE TIPS
Partial Hospitalization/Intensive Outpatient HCPCS: G0410-11, H0035, H2001, H2012, S0201, S9480, S9484-85 UBREV: 0905, 0907, 0912-13  Observation CPT: 99217-20  Visit Setting Unspecified CPT: 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55  Online Assessments CPT: 98969-72, 99421-23, 99444, 99457-58 HCPCS: G0071, G2010, G2012, G2061-63, G2250-52  Telephone Visits CPT: 98966-68, 99441-43  Exclusions:  • Members in hospice or using hospice services any time during the measurement year.  • Members who died any time during the measurement year.	Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	OF MEASURE	Documentation Tips: Discuss importance of timely recommended follow-up visits.  Outreach to members who cancel appointments and assist with rescheduling as soon as possible. Schedule follow-up appointments as soon as possible, particularly for recent discharges.  Coordinate care and share progress notes/updates between BH and PCP. Document substance abuse diagnosis and consistently document at each	OUD Weekly Drug Treatment Service HCPCS: G2067-70, G2072-73  OUD Weekly Non-Drug Service HCPCS: G2071, G2074-77, G2080  BH Outpatient CPT: 98960-62, 99078, 99201-05, 99211-15, 99241-45, 99341-45, 99347-50, 99381-87, 99391-97, 99401-04, 99411-12, 99483, 99492-94, 99510 HCPCS: G0155, G0176-7, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036-37, H0039, H0040, H2000, H2010-11, H2013-20, T1015 UBREV: 0510, 0513, 0515-17, 0519-23, 0526-29, 0900, 0902-04, 0911, 0914-17, 0919, 0982-83  Acute/Nonacute Inpatient Stay UBREV: 0100-01, 0110-14, 0116-24, 0126-34, 0136-44, 0146-54, 0156-60, 0164, 0167, 0169-74, 0179, 0190-94, 0199, 0200-04, 0206-14, 0219, 1000-02  Residential BH Treatment HCPCS: H0017-19, T2048  Partial Hospitalization/Intensive Outpatient HCPCS: G0410-11, H0035, H2001, H2012, S0201, S9480, S9484-85 UBREV: 0905, 0907, 0912-13  Observation CPT: 99217-20  Visit Setting Unspecified CPT: 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76, 99221-23, 99231-33, 99238-39, 99251-55  Online Assessments CPT: 98969-72, 99421-23, 99444, 99457-58 HCPCS: G0071, G2010, G2012, G2061-63, G2250-52  Telephone Visits CPT: 98966-68, 99441-43  Exclusions:  • Members in hospice or using hospice services any time during the measurement year.  • Members who died any time during the

#### **MEASURE**

### Use of Opioids from Multiple Providers (UOP)

18 years and over

### DESCRIPTION OF MEASURE

The percentage of members 18 years and older receiving prescription opioids for ≥ 15 days during the measurement year who received opioids from multiple providers.

### Three rates are reported.

- Multiple Prescribers:
   Members receiving
   prescriptions for opioids
   from four or more
   different prescribers
   during the current
   calendar year.
- 2. Multiple Pharmacies:
  Members receiving
  prescriptions for opioids
  from four or more
  different pharmacies
  during current calendar
  year.
- 3. Multiple Prescribers and Multiple Pharmacies: Members receiving prescriptions for opioids from four or more different pharmacies during the calendar year.

Note: A lower rate indicates better performances for all three rates.

#### **GOALS**

Reduce the number of adults prescribed opioids for  $\geq$  15 days by multiple providers. A lower rate indicates better performance for all three rates.

Member use of increasing number of prescribers or pharmacies may signal risk for uncoordinated care. Clinical coordination is encouraged so that providers can evaluate for risk of diversion, misuse or SUD. Providers are encouraged to communicate with each other for ideal management of member.

## COMPLIANCE CODES & MEASURE TIPS

### **Multiple Prescribers**

Members are considered out of compliance if they received prescription opioids from four or more different prescribers.

#### **Multiple Pharmacies**

Members are considered out of compliance if they received prescription opioids from four or more different pharmacies.

### Multiple Prescribers and Multiple Pharmacies

Members are considered out of compliance if they received prescription opioids from four or more different prescribers and/or four or more different pharmacies.

### The following opioid medications are excluded from this measure:

- Injectables
- Opioid cough and cold products
- lonsys® (fentanyl transdermal patch)
- Methadone for the treatment of opioid use disorder
- Single-agent and combination buprenorphine products used as part of medication assisted treatment of opioid use disorder.

This guide provides HEDIS coding information only, not necessarily payment guidance. Refer to state guidance for payment details and telehealth regulations.

Although the CPT II codes above are applicable for HEDIS measures, coding should always be validated per federal and state requirements.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

